Skip to main content
TipRanks
Go Ultimate75% OFF

Cooper Co (COO) AI Stock Analysis

671 Followers
COO

Cooper Co

(NASDAQ:COO)

Select Model
Rating:54Neutral
Price Target:$62.00â–²(2.11% Upside)
Action:reiterated
Date:09/15/26

COO’s score is held back primarily by sharply weaker TTM cash flow and compressed operating margins, despite solid revenue growth and a conservatively levered balance sheet. Technically, the stock is in a strong downtrend (well below key moving averages) even though it is extremely oversold. Valuation is moderate at ~18.5x earnings, while the latest earnings call was supportive on execution/cash flow and capital returns but tempered by soft near-term guidance and expected Q4 margin pressure.

Positive Factors
Revenue Growth and Gross MarginStrong revenue growth alongside a high gross margin indicates continued demand for Cooper’s medical device portfolio and meaningful product economics. If sustained, this combination can support reinvestment in innovation, commercial expansion, and market development across vision care and women’s health.
Negative Factors
Weak Cash ConversionThe sharp TTM decline in operating and free cash flow weakens earnings quality and reduces internally generated funds available for innovation, investment, debt reduction, and capital returns. Management reported quarterly improvement, but sustained recovery is important because cash conversion remains a key fundamental risk.

Cooper Co Key Performance Indicators (KPIs)

Revenue by SegmentShows how different parts of the business contribute to overall sales, highlighting strengths and potential areas for growth within the company's diverse operations.

$0.00$250.00M$500.00M$750.00M$1.00BJan 21Apr 21Jul 21Oct 21Jan 22Apr 22Jul 22Oct 22Jan 23Apr 23Jul 23Oct 23Jan 24Apr 24Jul 24Oct 24Jan 25Apr 25Jul 25Oct 25Jan 26Apr 26Jul 26
Chart Insights

CooperVision is the steady-growth engine—consistent organic lens demand and new product momentum (MiSight, daily silicone hydrogel) underpin resilience even as Asia softness and near-term margin pressure from FX, tariffs and inventory optimization bite. CooperSurgical is the faster-growth lever—fertility, genomics and capital equipment have materially lifted contribution since 2022, and management’s strategic review (broad external interest) could unlock value or introduce execution risk. Monitor how litigation payouts and any transaction proceeds affect buybacks, FCF allocation and near-term margin recovery.

Data provided by:The Fly

Cooper Co (COO) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%COO-14.61%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$11.55B
Dividend Yield
―
Average Volume (3M)
3.51M
Price to Earnings (P/E)
20.8
Beta (1Y)
0.55
Revenue Growth
4.73%
EPS Growth
43.89%
Country
US
Employees
15,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

Cooper Co Business Overview & Revenue Model

Company Description

The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact...

Cooper Co Earnings Call Summary

Earnings Call Date:Sep 09, 2026(Q3-2026)|% Change Since:-4.35%|Next Earnings Date:Dec 03, 2026
Earnings Call SentimentPositive

The call was broadly positive: the company delivered an earnings beat, record quarterly free cash flow, an 86% year-to-date free cash flow increase, a favorable tax resolution, substantial share repurchases and continued fertility and product momentum. These strengths were tempered by flat CooperVision revenue, U.S. channel destocking that will continue into Q4, legacy hydrogel declines, China and Asia Pacific challenges, near-term margin pressure and a higher expected fiscal 2027 tax rate. Management expressed confidence that inventory actions will be completed in Q4 and that increased commercial investment will support improved growth.

Positive Updates

Earnings Beat Expectations
Non-GAAP EPS increased 4% year-over-year to $1.15, including approximately $0.03 from tariff refunds. This was the company's 11th consecutive quarter exceeding consensus earnings expectations.

Negative Updates

CooperVision Revenue Flat in Q3
CooperVision revenue was $717 million, essentially flat year-over-year. Results in the Americas reflected proactive U.S. channel inventory reductions.

Company Guidance

For Q4, the company expects consolidated revenue of $1.057 billion to $1.08 billion, representing organic growth of 0% to 2%; CooperVision revenue of $692 million to $706 million, down 2% to flat organically; CooperSurgical revenue of $364 million to $374 million, representing organic growth of 4% to 6%; interest expense of roughly $25 million; a non-GAAP effective tax rate of roughly 16%; non-GAAP EPS of $1.05 to $1.09; and around $170 million of free cash flow, excluding litigation-related payments of roughly $272 million. MiSight growth is expected to be in the low teens in Q4, resulting in roughly 20% growth for this full year, while the company expects $2.2 billion of cumulative free cash flow in fiscal '26 to 2028 and, in fiscal 2027, its scheduled GILTI increase of roughly 2% to increase the non-GAAP effective tax rate from roughly 15.5% this year to roughly 17.5% in fiscal 2027.

Cooper Co Financial Statement Overview

Summary

Revenue growth is solid (~13.9% TTM) and the balance sheet is conservative (debt-to-equity ~0.31), but operating profitability compressed sharply (EBIT margin ~7.2% TTM vs ~15.4% prior annual) and cash generation deteriorated materially (operating cash flow ~$182M TTM vs ~$796M in FY2025; free cash flow down ~84%). Weak TTM cash conversion versus net income raises the biggest near-term quality risk.

Income Statement

74Positive

Balance Sheet

78Positive

Cash Flow

38Negative
Financial statement breakdown
BreakdownTTMOct 2025Oct 2024Oct 2023Oct 2022Oct 2021
Income Statement
Total Revenue4.24B4.09B3.90B3.59B3.31B2.92B
Gross Profit2.70B2.48B2.60B2.36B2.14B1.96B
EBITDA910.30M1.05B1.07B885.90M878.70M823.90M
Net Income570.30M374.90M392.30M294.20M385.80M2.94B
Balance Sheet
Total Assets12.67B12.39B12.32B11.66B11.49B9.61B
Cash, Cash Equivalents and Short-Term Investments154.70M110.60M107.60M120.90M138.20M95.90M
Total Debt2.54B2.78B2.58B2.57B2.76B1.48B
Total Liabilities4.34B4.16B4.23B4.11B4.32B2.66B
Stockholders Equity8.33B8.24B8.08B7.55B7.17B6.94B
Cash Flow
Free Cash Flow678.00M433.70M288.10M215.00M450.40M524.20M
Operating Cash Flow1.03B796.10M709.30M607.50M692.40M738.60M
Investing Cash Flow-361.50M-372.90M-764.60M-449.00M-1.83B-450.30M
Financing Cash Flow-641.00M-425.90M39.20M-173.90M1.19B-311.40M

Cooper Co Technical Analysis

Technical Analysis SentimentNegative
Last Price60.72

Price Trends

50DMA58.19Positive
100DMA65.39Negative
200DMA67.77Negative

Market Momentum

MACD0.85Positive
RSI48.78Neutral
STOCH18.96Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COO, the sentiment is Negative. The current price of 60.72 is below the 20-day moving average (MA) of 61.62, above the 50-day MA of 58.19, and below the 200-day MA of 67.77, indicating a neutral trend. The MACD of 0.85 indicates Positive momentum. The RSI at 48.78 is Neutral, neither overbought nor oversold. The STOCH value of 18.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COO.

Cooper Co Risk Analysis

Cooper Co disclosed 41 risk factors in its most recent earnings report. Cooper Co reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.Our business faces significant risks. These risks include those referenced below and may include additional risks and uncertainties not presently known to us or that we currently deem immaterial. Our business, financial condition and results of operations could be materially adversely affected by any of these risks, and the trading prices of our common stock could decline by virtue of these risks. These risks should be read in conjunction with the other information in this report.Q2, 2026
2.We identified a material weakness in our internal control over financial reporting related to an ineffective information technology (IT) general control for the U.S. operations within the CooperSurgical segment which, if not remediated appropriately or timely, could affect our ability to record, process and report financial information accurately and prepare financial statements within required time periods and could subject us to litigation or investigations, negatively affect investor confidence and adversely impact our stock price.Q3, 2024
3.Economic and trade sanctions could make it more difficult or costly for us to conduct our operations or achieve our business objectives.Q3, 2024

Cooper Co Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

COO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MMSIMMSI71Outperform$5.06B31.499.65%―9.34%33.77%
BLCOBLCO65Neutral$7.45B-67.36-1.73%―8.88%63.73%
STAASTAA59Neutral$1.28B2542.430.15%―42.36%―
BAXBAX58Neutral$13.33B-18.63-11.62%0.16%5.33%-164.67%
TFXTFX57Neutral$6.33B19.249.74%0.85%-29.30%―
COOCOO54Neutral$11.55B20.786.88%―4.73%43.89%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%COOBAXMMSISTAATFXBLCODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
COO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
COOCooper Companies60.72-11.43-15.84%
BAXBaxter International Inc25.768.1145.91%
MMSIMerit Medical84.490.800.96%
STAAStaar Surgical Company25.56-0.89-3.36%
TFXTeleflex159.5554.9252.49%
BLCOBausch + Lomb Corporation20.836.2142.48%

Cooper Co Corporate Events

Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures

Cooper Co Announces Leadership Reshuffle and Governance Changes

Neutral
Oct 27, 2026

On October 27, 2026, CooperCompanies announced a major leadership reshuffle, with long-time executive Albert G. White III resigning as president, CEO and board member, and independent director Walter M. Rosebrough Jr. taking over as interim executive...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 15, 2026